Avoro Capital Advisors LLC — 13F Holdings & Portfolio

CIK 1633313 · latest 13F-HR filed 2026-08-14

Avoro Capital Advisors LLC manages $11.14B in 13F-reported U.S. long-equity assets across 26 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are UTHR (13.52%), ASND (12.24%), KRYS (9.64%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 7; 16 existing positions rose in reported value and 2 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$11.14B

Long-equity book

Holdings
26

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+3 / −7 / ↑16 / ↓2

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

3 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 79.5%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 5, 2026.

Assets Under Management
$13.55B
Discretionary
$13.55B
Employees
19
Accounts
3
Address
110 GREENE STREET
SUITE 800
NEW YORK, NY 10012
Phone
(212) 937-4970
Name Title / Status Ownership Type
AGHAZADEH, BEHZAD ControlMANAGING DIRECTOR
since Sep 2017
Less than 5%Individual
AVORO CAPITAL L.P. ControlDIRECT OWNER
since May 2019
75% or moreDomestic Entity
CAMMAROSANO, NEIL ControlCHIEF FINANCIAL OFFICER
since May 2024
Less than 5%Individual
EPSTEIN, SCOTT, ANDREW ControlCHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
since Jun 2014
Less than 5%Individual
AGHAZADEH, BEHZAD Control
Indirect owner via AVORO CAPITAL L.P.
LIMITED PARTNER
since May 2019
50–75%Individual
AGHAZADEH, BEHZAD Control
Indirect owner via AVORO CAPITAL GP LLC
MEMBER
since May 2019
50–75%Individual
AVORO CAPITAL GP LLC Control
Indirect owner via AVORO CAPITAL L.P.
GENERAL PARTNER
since May 2019
General partner, trustee or managerDomestic Entity
KONG, GARHENG, ALBERT
Indirect owner via AVORO CAPITAL GP LLC
MEMBER
since May 2019
50–75%Individual
Ownership & leadership changes · 8 filings with changes since Feb 22, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Jun 4, 2024 filing
  • AddedCAMMAROSANO, NEIL · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ChangedEPSTEIN, SCOTT, ANDREW · title CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
May 13, 2019 filing
  • No longer listedAGHAZADEH, BEHZAD · LIMITED PARTNER · 75% or more · indirect via VENBIO SELECT ADVISOR L.P. · control person · listed since Sep 2017
  • No longer listedAGHAZADEH, BEHZAD · MEMBER · 75% or more · indirect via VENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · control person · listed since Sep 2017
  • No longer listedVENBIO SELECT ADVISOR L.P. · DIRECT OWNER · 75% or more · control person · listed since Sep 2017
  • No longer listedVENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via VENBIO SELECT ADVISOR L.P. · control person · listed since Sep 2017
  • AddedAGHAZADEH, BEHZAD · LIMITED PARTNER · 50–75% · indirect via AVORO CAPITAL L.P. · control person
  • AddedAGHAZADEH, BEHZAD · MEMBER · 50–75% · indirect via AVORO CAPITAL GP LLC · control person
  • AddedAVORO CAPITAL GP LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via AVORO CAPITAL L.P. · control person
  • AddedAVORO CAPITAL L.P. · DIRECT OWNER · 75% or more · control person
  • AddedKONG, GARHENG, ALBERT · MEMBER · 50–75% · indirect via AVORO CAPITAL GP LLC
Sep 28, 2017 filing
  • No longer listedADELMAN, ROBERT · MANAGER · 25–50% · control person · listed since Jan 2013
  • No longer listedGOODMAN, COREY, S. · MANAGER · 25–50% · control person · listed since Jan 2013
  • AddedAGHAZADEH, BEHZAD · LIMITED PARTNER · 75% or more · indirect via VENBIO SELECT ADVISOR L.P. · control person
  • AddedAGHAZADEH, BEHZAD · MEMBER · 75% or more · indirect via VENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · control person
  • AddedVENBIO SELECT ADVISOR L.P. · DIRECT OWNER · 75% or more · control person
  • AddedVENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via VENBIO SELECT ADVISOR L.P. · control person
  • ChangedAGHAZADEH, BEHZAD · title PORTFOLIO MANAGER → MANAGING DIRECTOR
Mar 29, 2016 filing
  • No longer listedBROOKE, PAUL, ALAN · MANAGER · 25–50% · control person · listed since Jan 2013
  • ChangedADELMAN, ROBERT · now a control person
Jan 29, 2015 filing
  • AddedAGHAZADEH, BEHZAD · PORTFOLIO MANAGER · Less than 5% · control person
  • AddedEPSTEIN, SCOTT, ANDREW · CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedADELMAN, ROBERT · title MANAGER AND CCO → MANAGER
Jan 13, 2015 filing
  • No longer listedVONEMSTER, KONRAD, HANS · MANAGER · 25–50% · control person · listed since Sep 2009
Mar 31, 2014 filing
  • AddedBROOKE, PAUL, ALAN · MANAGER · 25–50% · control person
  • AddedGOODMAN, COREY, S. · MANAGER · 25–50% · control person
  • ChangedADELMAN, ROBERT · title CHIEF COMPLIANCE OFFICER → MANAGER AND CCO; ownership Less than 5% → 25–50%
  • ChangedVONEMSTER, KONRAD, HANS · title MANAGING MEMBER → MANAGER; ownership 75% or more → 25–50%
May 9, 2013 filing
  • AddedADELMAN, ROBERT · CHIEF COMPLIANCE OFFICER · Less than 5%
  • ChangedVONEMSTER, KONRAD, HANS · title MANAGING MEMBER/CHIEF COMPLIANCE OFFICER → MANAGING MEMBER
Feb 22, 2012 filing (earliest on record)
  • ListedVONEMSTER, KONRAD, HANS · MANAGING MEMBER/CHIEF COMPLIANCE OFFICER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Avoro Capital Advisors LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 UNITED THERAPEUTICS CORP UTHR 91307C102 $1.51B 13.52% 2,777,777 SH
2 ASCENDIS PHARMA ASND K08588103 $1.36B 12.24% 5,111,111 SH
3 KRYSTAL BIOTECH INC KRYS 501147102 $1.07B 9.64% 2,888,888 SH
4 MADRIGAL PHARMACEUTICALS INC MDGL 558868105 $984.4M 8.84% 1,833,333 SH
5 ARGENX SE ARGX 04016X101 $927.8M 8.33% 1,000,000 SH
6 ARROWHEAD PHARMACEUTICALS INC ARWR 04280A100 $925.6M 8.31% 11,355,555 SH
7 KYMERA THERAPEUTICS INC KYMR 501575104 $857.1M 7.70% 7,474,747 SH
8 REVOLUTION MEDICINES INC RVMD 76155X100 $430.2M 3.86% 2,297,000 SH
9 CYTOKINETICS INC CYTK 23282W605 $425.9M 3.82% 4,999,999 SH
10 CELCUITY INC CELC 15102K100 $355.7M 3.19% 3,400,000 SH
11 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $351.8M 3.16% 6,555,555 SH
12 XENON PHARMACEUTICALS INC XENE 98420N105 $348.7M 3.13% 5,777,777 SH
13 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $338.2M 3.04% 7,188,888 SH
14 UNIQURE NV QURE N90064101 $309.9M 2.78% 6,727,777 SH
15 VERA THERAPEUTICS INC VERA 92337R101 $245.6M 2.21% 5,723,888 SH
16 TAYSHA GENE THERAPIES INC TSHA 877619106 $162.7M 1.46% 23,888,888 SH
17 OCULAR THERAPEUTIX INC OCUL 67576A100 $123.1M 1.11% 12,540,000 SH
18 DAMORA THERAPEUTICS INC DMRA 36322Q206 $98.4M 0.88% 3,783,000 SH
19 HEMAB THERAPEUTICS HLDGS INC COAG 423494103 $70.7M 0.63% 1,925,150 SH
20 GH RESEARCH PLC GHRS G3855L106 $48.4M 0.43% 1,800,000 SH
21 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $45.9M 0.41% 2,500,000 SH
22 SEPTERNA INC SEPN 81734D104 $44.8M 0.40% 1,337,500 SH
23 AVALO THERAPEUTICS AVTX 05338F306 $43.1M 0.39% 2,333,333 SH
24 FAETH THERAPEUTICS INC FTH 81728A207 $36.1M 0.32% 1,444,039 SH
25 WHITEHAWK THERAPEUTICS INC WHWK 00032Q104 $13.1M 0.12% 2,849,402 SH
26 LEXEO THERAPEUTICS INC LXEO 52886X107 $6.9M 0.06% 1,489,189 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $11.14B 26 0001104659-26-096427
2026-03-31 2026-05-15 $10.16B 33 0001104659-26-061754
2025-12-31 2026-03-16 $10.17B 34 0001104659-26-027799
2025-12-31 2026-02-17 $10.17B 34 0001104659-26-015748
Filer Information
Address
110 GREENE STREET
SUITE 800
NEW YORK, NY 10012
Phone
(212) 937-4975
Filing Manager
Avoro Capital Advisors LLC
NEW YORK, NY
Signatory
Scott Epstein
Chief Compliance Officer & COO